Research location

East Melbourne

Australia

Published trials29

Site observations29

Linked trials published29

Page1 / 1

Research activity in East Melbourne

Australia

CureCurrent currently publishes aggregate city-level research activity for this location: 29 trials and 29 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in East Melbourne

29 linked trials · page 1 of 1

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043 · 2025-07-29 · 1 site observation

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · 2025-03-27 · 1 site observation

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041 · 2025-03-10 · 1 site observation

Study of AZD0754 in Participants With Metastatic Prostate CancerNCT06267729 · 2024-03-12 · 1 site observation

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsNCT06188520 · 2023-12-05 · 1 site observation

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesNCT05786924 · 2023-04-18 · 1 site observation

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsNCT05307705 · 2022-05-11 · 1 site observation

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsNCT03093116 · 2017-03-07 · 1 site observation

LTFU for All Cell and Gene Therapy StudiesNCT06194461 · 2025-09-17 · 1 site observation

NOT_YET_RECRUITING

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerNCT06112379 · 2023-11-14 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast CancerNCT05498155 · 2022-11-07 · 1 site observation

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerNCT05367440 · 2022-06-02 · 1 site observation

ACTIVE_NOT_RECRUITING

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerNCT05221840 · 2022-02-07 · 1 site observation

ACTIVE_NOT_RECRUITING

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsNCT04672460 · 2020-12-21 · 1 site observation

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate CancerNCT04557059 · 2020-11-12 · 1 site observation

ACTIVE_NOT_RECRUITING

FM101 Safety, Tolerability, Efficacy Study in the Patients With Ocular HypertensionNCT04585100 · 2020-10-07 · 1 site observation

Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLCNCT02474355 · 2015-09-18 · 1 site observation

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast CancerNCT02129556 · 2014-12-01 · 1 site observation

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsNCT02043678 · 2014-03-30 · 1 site observation

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast CancerNCT02053636 · 2013-12-01 · 1 site observation

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsNCT01526928 · 2012-03-27 · 1 site observation

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02NCT00963417 · 2009-08-03 · 1 site observation

A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung CancerNCT00855894 · 2009-03-01 · 1 site observation

Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast CancerNCT00703326 · 2008-08-06 · 1 site observation

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DNCT00490139 · 2007-05-16 · 1 site observation

E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and TaxanesNCT00337103 · 2006-09-20 · 1 site observation

A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.NCT00448591 · 2006-09-01 · 1 site observation

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.NCT00605280 · 2005-09-01 · 1 site observation

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase EnzymesNCT00171912 · 2004-09-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.